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Research into the suppressive activity of CD4
+FoxP3
+ T regulatory cells (Treg) has defined a sublineage of CD4
+ 
cells that contribute to self-tolerance and resistance to autoimmune disease. Much less attention has been given to 
the potential contribution of regulatory sublineages of CD8
+ cells. Analysis of a small fraction of CD8
+ cells that 
target autoreactive CD4
+ cells through recognition of the MHC class Ib molecule Qa-1 in mouse and HLA-E in 
human has revitalized interest in CD8
+ Treg. Here we summarize recent progress and future directions of research 
into the role of this CD8
+ sublineage in resistance to autoimmune disease. Cellular & Molecular Immunology. 2008; 
5(6):401-406. 
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Introduction 
 
The adaptive immune response that defends the body against 
invasion by pathogenic microorganisms, including bacteria, 
viruses, fungi, parasites and cancer cells, is initiated by T 
cells. Although T cell clones express receptors for foreign 
antigen, positive selection of these clones by self-antigens 
during development in the thymus means that each clone has 
a measurable affinity for self-antigens. Although negative 
selection deletes strongly self-reactive T cells (1), this 
process is incomplete. T cells carrying receptors with 
intermediate and low affinity for self-antigen are routinely 
released into peripheral lymphoid tissues, where they may 
become activated, expand and possibly initiate autoimmune 
disease (2). This process is held in check by several cellular 
mechanisms, including specialized regulatory T cells (Treg) 
that suppress immune reactions to self. Treg belonging to the 
CD4
+ T cell lineage have been extensively studied (3) and 
drawn tremendous attention in the past few years. Although a 
sublineage of CD8
+ Treg was initially noted to display 
immunoregulatory activity (4), early analysis was hindered 
by limitations in technology. Recently, advanced molecular 
approaches to this problem and increased understanding of 
the immune system as a whole have allowed substantial 
progress to be made in this area. Here we review research 
into CD8
+ Treg and its contribution to self-tolerance.  
 
CD8
+ T cells as suppressor cells   
 
CD8
+ Treg were first observed by Gershon and colleagues in 
the early 1970’s (4). The ability to characterize T cell subsets 
using the CD8 surface molecule (termed Lyt2t) suggested 
that suppressive activity by a subpopulation of CD8
+ cells 
specifically inhibited T helper responses by CD8
-CD5
+ T 
cells (5). Subsequent studies determined that this inhibitory 
interaction reflected CD8
+ Treg recognition of Qa-1 on target 
CD4
+ cells (6).   
   Suppressive activity of CD8
+ T cells in autoimmune 
disease was first demonstrated in a murine model of multiple 
sclerosis (MS), experimental autoimmune encephalomyelitis 
(EAE). Animals that were deficient in CD8
+  T cells 
secondary to genetic mutation or antibody-dependent 
depletion displayed a chronic and persistent form of EAE 
that was characterized by a high frequency of disease relapse. 
Early experiments in mice and humans also suggested that 
CD8
+ Treg lysed encephalitogenic CD4
+ T cells (7, 8). The 
regulatory role of CD8
+ T cells was also observed in other 
autoimmune disease models, including autoimmune Herpes 
Stromal Keratitis and myocarditis. For example, CD8
+ T cell 
deficient mice developed more severe autoimmune 
myocarditis than heterozygous CD8
+/- mice or CD8 wild type 
controls (9). CD8-deficient mice were also more susceptible 
to relapse of autoimmune arthritis after immunization with 
self antigens (10), suggesting that regulatory activity of CD8
+ 
T cells might reside in the CD8
+ memory pool. CD8
+ Treg 
have also been implicated in the regulation of human 
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autoimmune diseases, including inflammatory bowl disease 
and MS (11, 12).  
 
Definition of CD8
+ Treg 
 
Although regulatory activity of CD8
+ T cells has been 
implicated in diverse settings, detailed studies of CD8
+ Treg 
have been hindered by the lack of a reliable surface marker to 
distinguish CD8
+ Treg from conventional CD8
+ cells. Several 
cell surface molecules have been associated with CD8
+ Treg 
in different experimental systems. For example, CD8
+CD28
- 
cells behave as regulatory T cells, since transfer of these cells 
(but not CD28
+ cells) into CD8-deficient mice significantly 
suppressed EAE (13). Moreover, CD8
+CD28
- but not 
CD8
+CD28
+ cells also inhibited IFN- production of myelin 
oligodendrocyte glycoprotein (MOG)-specific CD4
+ T cells 
through an interaction that required cell-cell contact. 
Similarly, CD8
+CD45R
+ and CD8
+CD122
+ T cells have been 
implicated in regulatory activity (14, 15). CD8
+ Treg may 
also be induced by plasmacytoid dendritic cells (pDC) from 
tumor ascites. These cells have an IL-10
+ CCR7
+ CD45RO
+ 
CD8
+ phenotype and can suppress tumor antigen-specific T 
cell effector function through IL-10 secretion (16). Similarly, 
immature conventional DC can induce CD8
+ Treg (17) and 
FoxP3
+ alloantigen-specific CD8
+CD28
- T suppressor cells 
can also be generated in vitro by tolerized endothelial cells 
(18). Primary suppressive CCR7
+CD45RO
+CD8
+ T cells 
have been isolated from human tumors, suggesting that they 
may contribute to the tumor-induced immunosuppressive 
network (19).   
 
Qa-1-restricted CD8
+ Treg 
 
The subset of Qa-1-restricted CD8
+ Treg is perhaps the 
best-defined of the candidate CD8
+ regulatory cells. This 
subpopulation of CD8
+ cells recognizes the MHC class Ib 
product Qa-1 (HLA-E in human) and suppresses the 
development and relapse of EAE, (20). Generation and 
analysis of Qa-1-deficient mice several years ago has allowed 
further definition of the role of Qa-1 in the generation and 
mediation of suppressive activity by this CD8
+ Treg subset. 
Mice lacking Qa-1-restricted CD8
+ Treg develop exaggerated 
immune responses to self antigen (21). However, Qa-1- 
deficient mice have not been sufficient to fully define the 
contribution of Qa-1-restricted CD8
+ T cells to immunological 
suppression, because of the bivalent interaction of Qa-1 with 
its receptors.   
   Presentation of peptide by the Qa-1 protein on APC 
activates antigen-specific CD8 cells. In addition, Qa-1 
complexed to the Qdm peptide engages the CD94/NKG2 
receptor expressed by CD8 cells and NK cells and attenuates 
the activities of these cells (22-24). As a result, the immune 
response phenotype of Qa-1-deficient mice reflects two 
opposing effects. Enhanced CD4-dependent immunity 
reflects loss of the Qa-1 target for CD8
+ Treg activity (21), 
while reduced CD4-dependent immunity results from lysis of 
activated CD4
+ cells by NK cells that are unencumbered by an 
inhibitory NKG2A-Qa-1/Qdm interaction (24). 
   To isolate and individually analyze these two Qa-1- 
dependent regulatory pathways, we exploited the fact that 
each Qa-1-dependent interaction utilizes distinct surface 
Qa-1 contact residues. Generation of a Qa-1 amino acid 
exchange mutation (Qa-1 D227K), which disrupts binding of 
Qa-1 to the CD8 co-receptor, prevents effective peptide 
presentation to CD8
+ cells (25). Cells expressing the Qa-1 
D227K mutation fail to present peptides to CD8
+ cells, but 
retain the ability to bind to NKG2A receptors on CD8
+ cells 
and NK cells. After targeting this Qa-1 point mutation into 
the Qa-1 locus and backcrossing to C57BL/6 mice, analysis 
of CD8
+ Treg activity in this Qa-1 knock-in strain revealed 
that Qa-1 D227K knock-in mice fail to develop CD8
+ Treg 
activity and display enhanced EAE by both PLP and MOG 
upon secondary immunization. This finding confirmed an 
important role for Qa-1 in generating and mediating CD8
+ 
Treg activity and also revealed the suppressive interaction on 
a molecular level, indicating that an MHC-TCR interaction 
depends on the CD8 co-receptor. 
      A second Qa-1 amino acid mutant (Qa-1 R72A) knock-in 
mouse strain was also developed that disrupts Qa-1 binding 
to NKG2A expressed by NK cells and CD8
+ cells, rendering 
CD4
+ cells vulnerable to NK and CD8
+ cells lysis, but 
sparing Qa-1-dependent peptide presentation to the TCR (24). 
Interestingly, genetic interruption of this interaction in Qa-1 
R72A knock-in mice allows development of robust CD8
+ 
Treg activity and complete resistance to the development of 
EAE.  
      These findings provide insight into the molecular 
constraints that dampen CD8
+ Treg activity. Qa-1/Qdm 
engagement of CD94/NKG2A on CD8
+ Treg transmits an 
inhibitory signal that attenuates CD8
+ Treg suppressive 
activity. The CD94/NKG2A/C/E receptors belong to the 
inhibitory NK receptor family (iNKRs) and express two 
immunoreceptor tyrosine-based inhibition motifs (ITIMs) 
that recruit SHP-1, which dephosphorylates signaling 
molecules and inhibits cellular activation. Although the 
CD94 chain can pair with other members of the NKG2 
family, including NKG2C or NKG2E [reviewed in (26)], 
relatively high levels of expression and stronger binding 
affinity of CD94/NKG2A for the Qa1-Qdm result in its 
dominance. As a result, Qa-1-dependent engagement of 
CD94/NKG2A receptors expressed by activated CD8
+ cells 
during viral infection downregulates cytotoxicity and 
production of pro-inflammatory cytokines. Interestingly, 
although only a small proportion of CD8
+ cells express 
NKG2A, according to immunofluorescence with available 
antibodies, the majority of CD8
+ cells specifically bind 
Qa-1-Qdm tetramers, perhaps allowing a more substantial 
impact of NKG2A ligation (27).   
   These data also suggest that the relative ratio of the two 
classes of Qa-1 peptide ligand – Qdm vs. non-Qdm (e.g. 
HSP60) peptide – on the surface of activated CD4
+ cells may 
determine susceptibility of these CD4
+ T cells to suppression 
by CD8
+ Treg. According to this view, engagement of 
NKG2A on CD8
+ Treg by the Qa-1-Qdm ligand on target 
CD4
+ cells inhibits Treg activity, while engagement of the Cellular & Molecular Immunology                                                                                   403 
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TCR expressed by CD8
+ Treg by Qa-1-non-Qdm peptide 
ligands, such as Hsp60 peptide, activates suppressive activity 
(28). Since the majority of murine
 CD8
+ T cells, including 
CD8
+ Treg, bind to Qa-1-Qdm tetramer and can express
 
functional receptors for both ligands, differential expression 
of Qa-1-Qdm and Qa-1-non-Qdm peptide ligands on 
activated Qa-1 CD4
+ target cells may decide the cell’s fate.   
   The tight regulatory control of CD8
+ Treg may be 
explained in part by their autoreactive recognition of Qa-1- 
restricted self antigens. Indeed, expansion of MHC class 
Ib-restricted CD8 cells in triple knock-out mice lacking Qdm 
(K
b-/-D
b-/-CIITA
-/-) induces autoimmune disease (29). Thus, 
regulation of Qa-1-restricted autoreactive cells through Qa-1- 
Qdm and CD94/NKG2A interaction may be essential to 
prevent CD8
+ autoimmunity.   
   Since autoreactive CD4
+ cells expressing the Qa-1 R72A 
point mutation fail to transmit an inhibitory signal via 
NKG2A to CD8
+ Treg, they were fully susceptible to 
inhibition and failed to induce EAE despite expression of the 
pathogenic 2D2
+ TCR transgene. These findings suggest that 
releasing the brakes on CD8
+ Treg activity by blockade of 
Qa-1-NKG2A interaction may facilitate new approaches to 
mobilizing CD8
+ Treg in the context of autoimmune disease. 
Indeed, antibody-dependent blockade of this interaction 
during ongoing EAE unleashed robust CD8-dependent Treg 
activity that attenuated disease progression and induced 
complete remission of this murine model of MS.   
 
HLA-E-restricted CD8
+ T r e g  i n  h u m a n  a n d  
regulation by CD94/NKG2A 
 
Recent reports have also demonstrated the participation of 
CD8
+ regulatory cells in controlling human MS (multiple 
sclerosis). Analysis of T cells from MS patients has shown 
that HLA-E restricted CD8
+ Treg can be cloned from both 
MS patients and healthy individuals. CD8
+ Treg isolated 
from MS patients lyse myelin-reactive CD4
+ T cells by a 
cytolytic process that is restricted by the non-classical MHC 
class Ib molecule HLA-E, the human homolog of Qa-1 in 
mouse (30).   
   Consistent with findings in the EAE model, HLA-E- 
restricted CD8
+ Treg cloned from patients during disease 
exacerbation express higher levels of CD94/NKG2A at their 
surface than CD8 cells cloned from MS patients in remission 
or CD8 cells from healthy controls, which correspond to their 
less cytotoxic activity against myelin-reactive CD4
+ T cells, 
indicating that CD94/NKG2A inhibitory receptors expressed 
by CD8
+ cells restrain their HLA-E-restricted suppressive 
activity. Moreover, antibody-dependent blockade of the 
HLA-E-CD94/NKG2A interaction enhanced lysis of auto- 
reactive CD4
+ T cell clones by HLA-E-restricted CD8
+ cells 
from MS patients (30). These findings also suggest that 
combination therapy with cloned HLA-E-restricted CD8
+ 
cells and anti-NKG2A antibody may result in long-term 
improvement and disease remission.   
      Glatiramer Acetate (GA; Copaxane), a synthetic 
copolymer of alanine, glutamic acid, lysine and tyrosine, was 
discovered during studies of EAE. Copaxane treatment can 
reduce exacerbations and suppress disability in relapsing- 
remitting MS (12). Although GA has received FDA approval 
as a treatment for MS, the mechanism of action of GA is 
unknown. Recent analyses have suggested that treatment of 
MS patients with GA results in up-regulation of regulatory/ 
suppressive GA-reactive CD8
+ T cells. GA-induced CD8
+ 
Treg expressed high levels of perforin and directly lysed 
CD4
+ T cells that presented GA by HLA-E (12). In contrast, 
untreated patients showed an overall deficit in CD8
+ T 
cell-mediated suppression, compared with healthy subjects. 
Recent studies have begun to define the role of Qa-1- 
restricted Treg in GA-dependent inhibition of murine EAE.   
 
Perspectives 
 
Phenotypic characterization of Qa-1-restricted CD8
+ Treg 
A major obstacle in the study of regulatory CD8
+ T cells has 
been the lack of a surface marker (like that for CD4
+ Treg) to 
identify and isolate this population. The use of polyclonal 
populations also hinders further study of the suppressive 
mechanism in vitro, due to the low frequency of CD8
+ Treg 
in this subpopulation.   
      Theoretically, the best potential marker for Qa-1- 
restricted CD8
+ Treg is the Qa-1 tetramer. However, there are 
obstacles to this approach that come from the peptide binding 
properties of Qa-1. The association between Qa-1 and its 
binding peptide is relatively weak, resulting in an unstable 
Qa-1/peptide complex, even with its dominant peptide Qdm. 
The dissociation rate of Qdm peptide from Qa-1 has a t½ of 
approximately 1.5 h at 37
oC, compared with peptide 
(SIINFEKL) binding to the MHC class Ia molecule, which 
dissociates with a t½ of 11-31 h (31). Peptides other than 
Qdm bind with even lower affinity to Qa-1, further hindering 
formation of a stable Qa-1 peptide complex, which is crucial 
for tetramer production. The repertoire of peptides presented 
by Qa-1 is substantially smaller than the repertoire of 
classical MHC molecules. These include the dominant Qdm 
peptide (31) as well as peptides derived from proteins, 
including heat shock protein 60 (Hsp60), insulin, Salmonella, 
GroEL, the TCR and the varicellovirus (UL49.5) (32-36). 
Peptides derived from T-cell receptor have been shown to be 
able to induce Qa-1-restricted CD8
+ Treg and inhibit the 
development of autoimmune disease (35, 37). Moreover, a 
signal peptide derived from the leader
 sequence of Hsp60sp 
bound to Qa-1 targets Qa-1-restricted CD8
+ T cells (28). 
Vaccination with  Hsp60sp-loaded dendritic cells (DCs) 
induces CD8
+ Treg that protect animals from subsequent 
induction of EAE. Whether other Hsp60sp-derived peptides 
function as targets for the Qa-1-restricted regulatory
 CD8
+ T 
cells is not known. A combination of surface markers and 
tetramer analysis may eventually allow full characterization 
of Qa-1-restricted CD8
+ Treg.   
   Recent studies have isolated a CD8
+ Treg clone derived 
from immunization of PLJ mice with a peptide derived from 
the T-cell receptor. This CD8
+ clone inhibits activation of 
V8.2
+CD4
+ T cells in the context of EAE (37). The clone, 404                                                                         Generation and Regulation of CD8
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which expresses the CD8 homodimer, recognizes a 
peptide derived from a conserved region of the TCR V8.2 
chain bound to Qa-1a. Since a single clone was analyzed in 
this study, whether all Qa-1-restricted CD8 Treg express 
CD8 is unclear. Most CD8
+TCR
+ T cells reside in 
IELs (CD8 IELs) and
  are present in mice genetically 
deficient in MHC class Ia molecules (38, 39), consistent with 
restriction by MHC class Ib (40). Further studies are 
warranted to determine whether Qa-1-restricted Treg express 
CD8
+  and, if so, whether they represent circulating
 
CD8 IELs or a separate lineage. 
 
Induction (priming) of CD8
+ Treg 
Unlike CD4
+FoxP3
+ Treg which arise naturally in the thymus, 
CD8 Treg activity must be induced by a primary antigen 
stimulation (although this type of induction is inefficient, 
since CD8
+ Treg activity is not developed in any given 
antigen response). The most efficient system for generating 
CD8
+ Treg occurs during the induction of EAE, at which 
CD8 suppressive activity develops during the primary 
immunization and can prevent subsequent induction of 
disease in the same host (21). Other approaches include 
T-cell vaccination (TCV), immunization with Qa-1-restricted 
peptide or DC loaded with such peptides (28, 35). CD8
+ Treg 
can also be induced by introducing antigens into immune 
privileged sites like the anterior chamber (AC) (41). However, 
Qa-1 restriction of the CD8
+ Treg has not been confirmed, 
although they share many features with Qa-1-restricted CD8
+ 
Treg.  
   The process and mechanisms by which CD8
+ Treg are 
induced is poorly understood. It is likely that costimulation is 
critical for their development. For example, the co- 
stimulatory molecule CD137 (4-1BB), which is expressed on 
activated CD8
+ T cells and can interact with its ligand 
4-1BBL on dendritic cells and tumor cells, is important for 
immunity against tumors and viruses as well as the 
generation of CD8
+ memory cells. More importantly, several 
reports have shown that immunization in combination with 
anti-4-1BB induced generation of CD8
+ Treg that profoundly 
inhibited CD4
+ T cell responses (42, 43). We have recently 
observed that administration of anti-4-1BB during both the 
induction and effector phase of CD8
+ Treg increased CD8 
suppressive activity (Kim et al., unpublished data).   
   Cytokines have also been implicated in the generation of 
CD8
+ Treg. CD8
+ Treg activity cannot be induced in 
IFN-R
-/- mice, indicating the essential role of IFN- in either 
generation or expression of CD8
+ Treg activity. On the other 
hand, CD8
+ Treg generated after immunization of IFN-
-/- 
mice are fully capable of suppressing CD4
+ T cell responses, 
suggesting that IFN- secretion of CD8
+ Treg does not 
contribute to suppressive activity (Lu et al., unpublished 
data).  
   Signal transducers and activators of transcription (STAT) 
proteins are latent cytoplasmic transcription factors that are 
phosphorylated by Janus kinases in response to interferon. 
Phosphorylated STAT proteins translocate to the nucleus, 
where they transiently turn on specific sets of genes. STAT1 
proteins can be activated by IFN treatment of CD8 T cells. 
Recent studies have shown that STAT1 signaling in
 CD8 T 
cells is required for their efficient expansion by promoting
 
the survival of activated CD8
+ T cells upon vaccinia viral 
infection in vivo, suggesting that the direct effect of IFN- on
 
CD8
+ T cells is mediated by STAT1. Since the IFNR 
expression on CD8
+ T cells is essential for the development 
of CD8 suppressive activity, the role of STAT1 in the 
generation of Qa-1-restricted CD8
+ suppressor cells will also 
be addressed.   
   Cytokines that stimulate CD8
+ T cells might also be 
important for the development of Qa-1-restricted CD8
+ Treg. 
One such example is IL-15. Qa-1-restricted CD8 as well as 
CD8
+ T cells restricted by other MHC class Ib molecules 
belong to a unique subpopulation of CD8
+ cells termed 
innate-CD8 with unique properties that include selection on 
hematopoietic cells, expression of memory markers, rapid 
production of cytokines, and dependence on IL-15 (44). The 
potential role of IL-15 in the development of Qa-1-restricted 
Treg requires further clarification. 
 
How do CD8
+ Treg inhibit immune responses?   
Several mechanisms have been implicated in the suppressive 
activity of CD8
+ Treg, including direct lysis of target cells 
and secretion of immunosuppressive cytokines. Possibly, 
different subsets of CD8
+ Treg utilize different inhibitory 
mechanisms, depending on the context of the immune 
reaction. Several early studies have described lysis of target 
cells by CD8
+ Treg. Further examination of the key 
molecules involved in CD8
+ Treg-mediated killing suggested 
that perforin-mediated cytolytic activity is necessary for 
suppression by CD8
+ Treg both in vivo and in vitro (45). 
Similar results obtained in studies of CD8
+ Treg isolated 
from human MS patients showed that perforin-mediated 
cytotoxicity is tightly constrained by the Qa1/NKG2A 
interaction (30).   
   Perforin-dependent lysis may not be the only mechanism 
utilized by Qa-1-restricted CD8
+ Treg. CD8
+CD122
+ Treg 
can secrete IL-10 to exert inhibitory activity (46). Although 
IFN- can inhibit immune responses, as discussed above, 
IFN- is more likely to play a role in priming Qa-1-restricted 
Treg rather than mediating suppressive function (Lu et al., 
unpublished data).   
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